Browse by Medical Category
Researchers at the Massachusetts General Hospital Institute for Heart, Vascular and Stroke Care and Vanderbilt Heart and Vascular Institute have found a chemical biomarker in blood that can predict diabetes risk more than a decade before the onset of the disease.
A study led by Robert Gerszten, MD, director of clinical and translational research at the Massachusetts General Hospital Institute for Heart, Vascular and Stroke Care, identifies a biomarker that can predict diabetes risk.
A study, led by Robert Gerszten, MD, director of clinical and translational research at the Massachusetts General Hospital Corrigan Minehan Heart Center, identifies a biomarker that could predict the onset of Type 2 diabetes up to 12 years in advance.
ESTABLISHED IN 2011 by ECOR and the MGH Research Advisory Council, the MGH Research Scholars program provides five years of unrestricted funding to give innovative investigators the flexibility to pursue projects that may lead in unexpected directions. Supported by philanthropic gifts, the program expanded from the first group of five recipients to eight scholars in 2012.
Measuring the levels of small molecules in the blood may be able to identify individuals at elevated risk of developing type 2 diabetes as much as a decade before symptoms of the disorder appear.
Using a system that analyzes blood samples with unprecedented detail, a team led by MGH researchers has developed the first "chemical snapshot" of the metabolic effects of exercise.
Study of 'planned' heart attacks identifies markers that could improve treatment, save lives.
Back to Top